SELLAS Phase 3 Surge: How Three Halts Shaped the Nov. 17 Move in SLS
Nasdaq halted SELLAS shares three times on Nov. 17 after positive Phase 3 leukemia data. The stock closed the regular session at $19.15, well below a $34.19 pre-market high, and a $150 million offering was filed after the close.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) said in an 8-K filed at 7:14 a.m. ET on Nov. 17, during a pre-market trading halt, that its Phase 3 REGAL trial of the leukemia vaccine galinpepimut-S met its survival goal. Median survival was 24.0 months versus 14.7 months for best available treatment. At 4:14 p.m. ET, after the close, the company filed for a $150 million common stock offering.
Three halts, and still a 20% slide in the regular session
Nasdaq halted SLS three times on Nov. 17: once for the news and twice for volatility. A halt stops trading for a set period but does not decide where the stock trades when it reopens. SLS closed the regular session at $19.15, 156.36% above the Nov. 16 close of $7.47 and 20.21% below its pre-market close of $24.00.
How news halts and volatility pauses work
A trading halt stops all trades in a stock for a period. In a news-pending halt, the exchange holds trading until a company's announcement is out, so buyers and sellers can read it before trading resumes.
A volatility pause starts automatically when a price moves outside a band set around recent prices. It gives the market a short break before trading restarts.
A news halt first, then two volatility pauses
Nasdaq halted SLS at 6:55 a.m. ET on Nov. 17, with news pending. The 8-K arrived at 7:14 a.m., trading resumed at 7:30 a.m., and the company had scheduled a webcast for 7:45 a.m.
Pre-market, shares reached $24.00 by the last trade at 9:29 a.m., 221.29% above the Nov. 16 close. The pre-market range ran from $7.46 to $34.19. Volume was 25.71 million shares, against an average of about 6.5 million a day over the prior 10 sessions.
Volatility pauses followed right after the 9:30 a.m. open, from 9:35:35 to 9:45:35 and from 9:50:03 to 9:55. The regular session then ranged from $16.70 to $24.89, on 88.23 million shares. The float, the shares available for public trading, is about 200 million.
After the close, shares fell 10.5% in after-hours trading, from $19.15 to $17.14, on 6.44 million shares. The offering filing landed at 4:14 p.m., 14 minutes into that session. It is not clear how much of the decline came before the filing.
The stock had also moved before the news. It rose 6.96% in after-hours trading on Nov. 16, to $7.99, and the reason for that gain is not clear. Over the sessions from Oct. 19 to Nov. 16, it fell 28.79%, with a low of $7.14 on Nov. 6 and a 14.71% drop on Oct. 28, the day the company announced the 80th death event in REGAL.
What the result and the filing say
The company said the analysis was run after the pre-specified 80th death. GPS showed a 41% reduction in the risk of death, a hazard ratio of 0.59 and a two-sided p-value of 0.035, according to the company. The offering is a sale of new shares by the company, and the preliminary prospectus said its terms were subject to completion. It cited the Nov. 16 close of $7.47 as the last reported price.
The slide from $24.00 to $19.15 during the regular session came before the offering filing.
What the company said about the trial
- GPS was generally well tolerated, with mostly mild to moderate side effects, mainly injection site reactions.
- Few patients went on to stem cell transplant, and they were equally split between the GPS and control arms.
- The company plans to meet the FDA about an accelerated filing strategy and to prepare a Biologics License Application (BLA) for the first half of 2027.
- Secondary endpoints and other pre-specified analyses are still being evaluated.
What comes next
- Pricing and final size of the stock offering. The Nov. 17 filing was a preliminary prospectus supplement.
- The company's meeting with the FDA on filing strategy.
- A BLA submission, which the company targets for the first half of 2027.
- Detailed REGAL results, which the company said will be presented at a major medical conference and submitted to a peer-reviewed journal.
- Phase 2 data for SLS009 in relapsed or refractory AML, which the company is set to present at ASH 2026.
Bottom line
The halts controlled when the REGAL data reached the market on Nov. 17. They did not control the price. SLS reached $34.19 in pre-market, closed the regular session at $19.15 and traded at $17.14 in after-hours following the offering filing.
This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.
This article is for informational purposes only and is not investment advice.




